Lansoprazole, a known H + /K + -ATPase inhibitor, is currently used as a therapeutical option for the initial treatment of gastroesophageal reflux disease. Recently, lansoprazole has been found to be an inhibitor of cytosolic PHOSPHO1 (a phosphatase which hydrolyses phosphocholine and phosphoethanolamine), providing a possible therapeutical target to cure pathological mineralization. Since PHOSPHO1 is present inside matrix vesicles, we tested the effect of lansoprazole on matrix vesicles containing several key enzymes for the mineralization process including tissue-nonspecific alkaline phosphatase. We found that lansoprazole can inhibit in an uncompetitive manner tissue-nonspecific alkaline phosphatase. A K i value of 1.74 ± 0.12 mM has been determined for the inhibition of tissue-nonspecific alkaline phosphatase by lansoprazole. Lansoprazole, currently used for treating gastroesophageal disease, by inhibiting PHOSPHO1 and tissue-nonspecific alkaline phosphatase could prevent hydroxyapatite-deposition disease and could serve as an adjunct treatment for osteoarthritis.
INTRODUCTION
Lansoprazole is a selective H + /K + -ATPase inhibitor (Gremse, 2001) . Acid suppression with proton pump inhibitors is now the preferred treatment option for the initial treatment of gastroesophageal reflux disease (DeVault & Castel, 1999; Der, 2003; Kivioja et al., 2004; Shi & Klotz, 2008) . Lansoprazole is used for the short term treatment of erosive reflux oesophagitis, active gastric ulcer, active duodenal ulcer and the treatment of non-steroidal anti-inflammatory drug-induced gastric and duodenal ulcers. It has been also approved for the long-term treatment of healed reflux oesophagitis, healed duodenal ulcer, the treatment of hypersecretory conditions as Zollinger-Ellison syndrome (Gremse, 2001) . Lansoprazole, as other substituted 2-pyridylmethylsulfinyl benzimidazoles such as omeprazole, pantoprazole and rabeprazole are weak bases, accumulating inside the acidic environment of H + /K + -ATPase. At acidic pH they undergo an acid catalyzed rearrangement to a cationic sulfenamide, forming disulfides with cysteines of the H + /K + -ATPase proton pump (Besancon et al., 1997) . Although no use of lansoprazole has been reported to cure bone diseases, it was recently reported that lansoprazole has the ability to modulate in vitro mineralization induced by matrix vesicles (MVs), isolated from calvaria of tissue-nonspecific alkaline phosphatase (TNAP) null mice, by inhibiting PHOSPHO1 (Narisawa et al., 2007) . The phosphatase PHOSPHO1 is a soluble enzyme which hydrolyzes specifically phosphoethanolamine and phosphocholine (Pchol) (Roberts et al., 2005) and contributes to increase P i inside MVs thereby leading to mineralization (Roberts et al., 2006) . Osteoblasts and hypertrophic chondrocytes can initiate mineralization by releasing MVs (Anderson, 2007; Kirsch, 2007) . MVs are involved in the initial step of mineralization by promoting the formation of hydroxyapatite (HA) inside MVs. Once the crystals have reached a certain size, they rupture the MV membranes and migrate into the extracellular matrix. This is followed by HA propagation outside the MVs, supplemented by the Ca 2+ and P i through circulation, and ultimately HA fills up the space between collagen fibers of the skeletal matrix (Anderson, 2007; Kirsch, 2007) . Although P i is continuously supplied by circulation, other sources of P i sustain the mineralization process. One likely source of P i could come from the hydrolysis of phosphomonoesters by 5'-AMPase (Einhorn et al., 1985) , ATPases (Hsu & Anderson, 1996; Hsu et al., 1999) , PHOSPHO1 (Roberts et al., 2004; and tissue-nonspecific alkaline phosphatase (TNAP) (Register et al., 1986; Balcerzak et al. 2003; Anderson et al., 2004) . Inhibitors of any phosphomonoesterase enzymes should affect the mineralization process, providing a possible therapeutical target to cure pathological mineralization, such as osteoarthritis, crystal-deposition arthritis, atherosclerosis and tumor calcification (in breast cancer) (Andersen, 2007; Kirsch, 2007) . Since PHOSPHO1, is also entrapped in MVs, we tested the effect of lansoprazole on MVs, containing several key enzymes implicated in the mineralization process, including TNAP. We confirmed the therapeutical potential of lansoprazole, as inhibitor of PHOSPHO1 (Roberts et al., 2007) and in addition we found that lansoprazole can also inhibit in an uncompetitive manner TNAP. Therefore the inhibition properties of lansoprazole toward PHOS-PHO1 and TNAP, implicated both in the mineralization process could boost the efficiency of lansoprazole to inhibit mineral formation.
MATERIALS AND METHODS
Isolation of matrix vesicles. MVs were isolated from 17-day-old chicken embryos (Balcerzak et al., 2007) . They were stored in ice cold synthetic cartilage lymph (SCL) containing 2 mM CaCl 2 and 1.42 mM NaH 2 PO 4 in addition to 100 mM NaCl, 1.83 mM NaHCO 3 , 12.70 mM KCl, 0.57 mM MgCl·6H 2 O, 0.57 mM Na 2 SO 4 , 63.50 mM sucrose, 5.55 mM d-glucose, 16.5 mM TES pH 7.4 (Wu et al., 1997) . Protein concentration in the vesicles was determined by the method of Bradford (Bradford, 1976) .
Isolation of tissue-nonspecific alkaline phosphatase by phosphatidylinositol-phospholipase C treatment. MVs were incubated in SCL medium containing 6 µM ZnCl 2 , 20 mM MgCl 2 and 1.5 × 10 -3 units phosphatidylinositol phospholipase C (PI-PLC) /µg MVs proteins for 6 h at 37°C under gentle vortexing (Zhang et al., 2005) . The supernatant and the pellet were separated by centrifugation at 100 000 × g for 30 min. The supernatant containing tissue-nonspecific alkaline phosphatase was collected. For comparison, commercial tissue-nonspecific alkaline phosphatase from porcine kindey was purchassed from Sigma.
Fluorescence determination of phosphocholine hydrolysis. The fluorescence of resorufin induced by the reaction of 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red PLD Kit, Molecular Probes) and H 2 O 2 produced by the oxidation of Chol to betaine was monitored at 585 nm after sample excitation at 571 nm on a F-4500 Hitachi Fluorescence Spectrophotometer. Slits for excitation and emission were set at 2.5 and 5 nm, respectively. MVs (20 µg protein/ml) in 50 mM Tris/HCl, pH 7.4, 140 mM NaCl without any additions or in the presence of inhibitors such as 1-5 mM levamisole , 0.1 mM vanadate or 1 mM lansoprazole were mixed with 500 µl of reaction buffer containing 50 µM Amplex reagent, 1 U/ml of horseradish peroxidase (HRP) and 1 U/ml of choline oxidase from Alcaligenes sp. (Balcerzak et al., 2006) .
Phosphomonoesterase activity assays. The phosphomonoesterase (PME) activity of TNAP was measured (at 420 nm) with 10 mM p-nitrophenyl phosphate (pNPP) as substrate (Engstrom, 1961) in the reaction solution containing 25 mM piperazine and 25 mM glycylglycine at pH 10.4 and at 37°C. One unit of the activity was defined as the amount of enzyme hydrolyzing 1 µmol of substrate per min.
RESULTS

Lansoprazole inhibition of phosphocholine hydrolysis by tissue-nonspecific alkaline phosphatase
To determine PHOSPHO1 activity in MVs, addition of exogenous Pchol (a substrate for PHOSPHO1 as well as for other phosphomonesterase enzymes such as TNAP), we measured the hydrolysis of Pchol, using the fluorescence of resorufin. MVs (20 µg protein/mL) were able to hydrolyze completely within 20 min at pH 7.4, 1 µM exogenous-Pchol by forming choline and P i (Fig. 1) . Since PHOSPHO1 is a cytosolic enzyme entrapped inside MVs, this suggested either that phosphocholine was transported inside MVs and hydrolyzed inside by PHOSPHO1 and/or that phosphocholine was hydrolyzed by MV-phosphomonoesterase enzymes such as TNAP pointing to the extracellular side. Since MVs are enriched in GPI-anchored TNAP, we checked the phosphocholine hydrolysis by using TNAP inhibitors. Addition of TNAP inhibitor (either 5 mM levamisole or 0.1 mM vanadate) prevented almost completely the Pchol hydrolysis, indicating that TNAP was implicated in the hydrolysis of Pchol. Addition of 1 mM lansoprazole, a PHOSPHO1 inhibitor (Roberts et al., 2007) 
inhibited partially the Pchol
Lansoprazole is an uncompetitive inhibitor of alkaline phophatase hydrolysis by MVs, suggesting that PHOSPHO1 was implicated in the Pchol hydrolysis and that the remaining hydrolysis activity was due to other phosphomonesterase enzymes. To confirm the origin of enzymatic inhibition by lansoprazole, TNAP was isolated from MVs after PI-PLC treatment and centrifugation. The released TNAP from MVs was in the supernatant, while the PI-PLC treated MVs without TNAP was pelleted down. We observed that 1 mM lansoprazole moderately inhibited the Pchol hydrolysis by isolated TNAP in the supernatant (Fig. 2) , while 0.1 mM vanadate and 5 mM levamisole (Fig. 2) completely inhibited its activity. Lansoprazole also inhibited the Pchol hydrolysis at pH 7.4 (Fig. 3) as well as pNPP hydrolysis at pH 10.4 (Fig. 4) by commercial TNAP from porcine kidney, confirming its inhibitory activity to TNAP.
Determination of K i value of lansoprazole
The pNPP-hydrolysis inhibition of lansoprazole on TNAP at pH 10.4 was determined by using Lineweaver-Burk plots. Four distinct lansoprazole concentrations from 0, 0.5, 1, and 1.5 mM and pNPP concentrations ranging from 15 mM to 250 mM served to determine the kinetic parameters (Table 1 ). An apparent K i value of 1.74 ± 0.12 mM was determined and our findings indicated that lansoprazole inhibited the hydrolysis by TNAP in an uncompetitive manner. 
DISCUSSIONS
In this work, we found that lansoprazole, a potent inhibitor of PHOSPHO1 (Roberts et al., 2006) inhibited the Pchol hydrolysis in an uncompetitive manner by TNAP within MVs or by isolated TNAP at pH 7.4. A K i value of 1.74 ± 0.12 mM for the uncompetitive inhibition of pNPP at pH 10.4 by alkaline phosphatase with lansoprazole was found while a K i value of 28 ± 9.21 µM was obtained for lansoprazole inhibiting PHOSPHO1 (Roberts et al., 2006) . Due to the fact that PHOSPHO1 is a cytosolic enzyme entrapped inside MVs, while TNAP active site is located toward the extracellular matrix, lansoprazole could inhibit not only PHOSPHO1 but also TNAP despite its relatively higher K i value than that of PHOSPHO1. Although lansoprazole may not be the best therapeutical option for curing osteoarthritis diseases characterized by HA deposits, it may contribute as an adjunct therapy to cure osteoarthritis. This is especially true for patients being treated for gastroesophageal reflux disease with lansoprazole and having osteoarthritis. Lansoprazole, used for the treatment of gastroesophageal reflux disease, under acidic conditions undergoes to an acid catalyzed rearrangement to a cationic sulfenamide, forming disulfides with cysteines of the H + /K + -ATPase proton pump and inhibiting it. However, in the case of TNAP and PHOSPHO1, the inhibition of phosphomonoesterase activity can occur at pH 7.4 and therefore the mode of action is different. The rationale to cure pathological calcification by targeting TNAP and PHOSPHO1 within MVs is supported by the fact that not only MVs appear to initiate skeletal mineralization, but MVs are also involved in a variety of pathological calcifications (Anderson 1983; 1988; Ali, 1985; Kirsch, 2007) . Calcified diseases associated with osteoarthritis are correlated with the deposition of calcium pyrophosphate dihydrate (CPPD) crystals (25-55% of the time) and/or of the deposition of basic calcium phosphate (BCP) crystals (35-70% of the time) consisting of carbonate-substituted HA and octacalcium phosphate (Gordon et al., 1984; Carrol et al., 1991; Derfus et al., 2002; Nalbant et al., 2003) . It has been proposed that MVs could be the target of a potential therapy for pathologic calcifications (Anderson, 2007) . MVs of affected cartilage in osteoarthritis increases TNAP activity as much as 30-fold and induce HA deposition (Ali, 1985) indicating that TNAP (Narisawa et al., 2007; Sidique et al., 2009 ) could be a likely drug target, among other enzymes implicated in the mineral formation. Indeed, one likely source of P i in the extracellular matrix to sustain HA nucleation and growth is obtained through the activity of TNAP (either within cells or within MVs) (Register et al., 1986; Balcerzak et al., 2003; Anderson et al., 2004) which can produce P i but can also hydrolyze PP i , an inhibitor of HA formation (Register & Wuthier, 1985) . A complete inhibition of TNAP may decrease HA deposition; however, it will increase calcium pyrophosphate dihydrate (CPPD) deposition, since accumulation of PP i in the presence of Ca 2+ leads to CPPD. Therefore, a partial inhibition of TNAP could be more effective than a complete inhibition to prevent calcified diseases. Levamisole, a known TNAP inhibitor, has been used for curing rheumatoid arthritis (McGill, 1976; Miller et al., 1980) suggesting that TNAP could serve as drug target for preventing HA deposition in cartilage. 
